Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide Consumer Healthcare net revenue was flat at $598 mil. during the second quarter, Wyeth announces July 20. Net revenue for the division worldwide during the first six months of 2006 decreased 5% to $1.16 bil. when compared to the first six months of 2005. An increase in sales of Advil and Centrum vitamins helped offset losses caused by lower sales of Robitussin, Dimetapp and Advil Cold & Sinus, which resulted from increased retailer restrictions on pseudoephedrine-containing products, the company says. The earnings also reflect the loss of Solgar vitamin sales; the brand was divested to NBTY in the third quarter of 2005 (1"The Tan Sheet" Jan. 16, 2006, p. 13). Wyeth Nutrition's second-quarter net revenue increased 13% over the prior-year period to $300 mil...
You may also be interested in...
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.